2592
This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2).
 ( potential therapeutic event: effects ,  331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2): Subject, 331: Subject.Population, women: Subject.Gender, postmenopausal: Subject.Age, combined RLX and ALN: Treatment, osteoporosis: Treatment.Disorder, RLX: Treatment.Drug, ALN: Treatment.Drug, RLX: Combination.Drug, ALN: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: effects ,  331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2): Subject, 331: Subject.Population, women: Subject.Gender, postmenopausal: Subject.Age, combined RLX and ALN: Treatment, osteoporosis: Treatment.Disorder, RLX: Treatment.Drug, ALN: Treatment.Drug, RLX: Combination.Drug, ALN: Combination.Drug) 